Anda di halaman 1dari 19

54

DAFTAR PUSTAKA

1. Setiati S, Alwi I, Sudoyo AW, Stiyohadi B, Syam AF. Buku ajar ilmu
penyakit dalam jilid I. VI. Jakarta: InternaPublishing; 2014:1132-53.
2. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, Simone GD, et
al. Heart disease and stroke statistics--2010 update: a report from the
American Heart Association. Circulation. 2010;121(7):e46-e215.
3. Ri D. Profil Kesehatan Indonesia 2008. J Pers Soc Psychol. 2009;51(6):40.
4. Lilly LS. Pathophysiology of heart disease: a collaborative project of medical
students and faculty. Vol V. V. (Lilly LS, ed.). Lippincott Williams &
Wilkins; 2011: 216-43.
5. Koukouvou G, Kouidi E, Iacovides A, Konstantinidou E, Kaprinis G,
Deligiannis A. Quality of life, psychological and physiological changes
following exercise training in patients with chronic heart failure. J Rehabil
Med. 2004;36(1):36-41.
6. van Tol BAF, Huijsmans RJ, Kroon DW, Schothorst M, Kwakkel G. Effects
of exercise training on cardiac performance, exercise capacity and quality of
life in patients with heart failure: a meta-analysis. Eur J Heart Fail.
2006;8(8):841-50.
7. Garin O, Ribera A, Rajmil L, Valderas JM, Guillemin F, Revicki D, et al.
Assessing health-related quality of life in patients with heart failure: a
systematic, standardized comparison of available measures. Heart Fail Rev.
2014;19(3):359-67.
8. Austin BA, Wang Y, Smith GL, Vaccarine V, Krumholz HM, McNamara
RL. Systolic function as a predictor of mortality and quality of life in long-
term survivors with heart failure. Clin Cardiol. 2008;31(3):119-24.
9. Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG,
Marburger CT, et al. Pathophysiological characterization of isolated diastolic
heart failure in comparison to systolic heart failure. JAMA.
2002;288(17):2144.
55

10. Hobbs FDR, Kenkre JE, Roalfe AK, Davis RC, Hare R, Davies MK. Impact
of heart failure and left ventricular systolic dysfunction on quality of life: a
cross-sectional study comparing common chronic cardiac and medical
disorders and a representative adult population. Eur Heart J.
2002;23(23):1867-76.
11. Fuster V, O’Rourke RA, Walsh R, Poole-Wilson P. Hurst’s the heart, 12th
edition. Vol 2007.; 2007:719-38.
12. Fauci A, Braunwald E, Kasper D, Hauser S, Longo D, Jameson J, et al.
Harrison’s principles of internal medicine, 17th edition.; 2008:1443-54.
13. Heart failure Risk factors - Mayo Clinic.
http://www.mayoclinic.org/diseases-conditions/heart-failure/basics/risk-
factors/con-20029801. Accessed December 10, 2015.
14. Kumar V, Abbas AK, Fausto N, Mitchell R. Robbins basic pathology, 8th
edition.; 2007:578-82.
15. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG et
al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines
for the Diagnosis and Management of Heart Failure in Adults A Report of the
American College of Cardiology Foundation/American Heart Association
Task Force on Practice Guidelines Developed . J Am Coll Cardiol.
2009;53(15):e1-e90.
16. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk
factors for congestive heart failure in US men and women: NHANES I
epidemiologic follow-up study. Arch Intern Med. 2001;161(7):996-1002.
17. Doggrell SA. CHARMed – the effects of candesartan in heart failure. Expert
Opin Pharmacother. April 2005.
18. Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR,
Rodeheffer RJ, et al. Burden of systolic and diastolic ventricular dysfunction
in the community: appreciating the scope of the heart failure epidemic. JAMA.
2003;289(2):194-202.
19. Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, et al.
Relation of disease pathogenesis and risk factors to heart failure with
56

preserved or reduced ejection fraction: insights from the framingham heart


study of the national heart, lung, and blood institute. Circulation.
2009;119(24):3070-77.
20. Russell SD, Saval MA, Robbins JL, Ellestad MH, Gottlieb SS, Handberg EM,
et al. New York Heart Association functional class predicts exercise
parameters in the current era. Am Heart J. 2009;158(4 Suppl):S24-S30.
21. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al.
2013 ACCF/AHA guideline for the management of heart failure: a report of
the American College of Cardiology Foundation/American Heart Association
Task Force on practice guidelines. Circulation. 2013;128(16):e240-e327.
22. Madhok V, Falk G, Rogers A, Struthers AD, Sullivan FM, Fahey T, et al. The
accuracy of symptoms, signs and diagnostic tests in the diagnosis of left
ventricular dysfunction in primary care: a diagnostic accuracy systematic
review. BMC Fam Pract. 2008;9:56.
23. Jimeno Sainz A, Gil V, Merino J, García M, Jordán A, Guerrero L, et al.
Validity of Framingham criteria as a clinical test for systolic heart failure. Rev
clínica española. 2006;206(10):495-98.
24. Maestre A, Gil V, Gallego J, Aznar J, Mora A, Martín-Hidalgo A, et al.
Diagnostic accuracy of clinical criteria for identifying systolic and diastolic
heart failure: cross-sectional study. J Eval Clin Pract. 2009;15(1):55-61.
25. Watson RD, Gibbs CR, Lip GY. ABC of heart failure. Clinical features and
complications. BMJ. 2000;320(7229):236-39.
26. Wilkins LW, Tajik AJ, M.D., et al. Cardiovascular physiology concepts 2nd
ed. Lippincott Williams & Wilkins; 2013:205-13.
27. Ciampi Q, Villari B. Role of echocardiography in diagnosis and risk
stratification in heart failure with left ventricular systolic dysfunction.
Cardiovasc Ultrasound. 2007;5:34.
28. Naik MM, Diamond GA, Pai T, Soffer A, Siegel RJ. Correspondence of left
ventricular ejection fraction determinations from two-dimensional
echocardiography, radionuclide angiography and contrast cineangiography. J
Am Coll Cardiol. 1995;25(4):937-42.
57

29. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA,
et al. Recommendations for chamber quantification. Eur J Echocardiogr.
2006;7(2):79-108.
30. Cella DF. Quality of life: concepts and definition. J Pain Symptom Manage.
1994;9(3):186-92.
31. CDC - Concept - HRQOL. http://www.cdc.gov/hrqol/concept.htm. Accessed
January 15, 2016.
32. Indonesia U, Suharsono T, Keperawatan FI, Magister P, Keperawatan I.
Universitas Indonesia .Dampak home based exercise training terhadap
kapasitas fungsional dan kualitas hidup pasien. 2011.
33. Lam CL, Lauder IJ. The impact of chronic diseases on the health-related
quality of life (HRQOL) of Chinese patients in primary care. Fam Pract.
2000;17(2):159-166.
34. Dunderdale K, Thompson DR, Miles JN V, Beer SF, Furze G. Quality-of-life
measurement in chronic heart failure: do we take account of the patient
perspective? Eur J Heart Fail. 2005;7(4):572-82.
35. Dahlan MS. Statistik untuk kedokteran dan kesehatan. 6th ed. Jakarta:
Epidermiologi Indonesia; 2014:223-34
36. Sakata Y, Shimokawa H. Epidemiology of heart failure in asia. Circ J.
2013;77(9):2209-17.
37. WHO | Definition of an older or elderly person.
http://www.who.int/healthinfo/survey/ageingdefnolder/en/. Accessed May
30, 2016.
38. Lam CSP. Heart failure in southeast asia: facts and numbers. ESC Hear Fail.
2015;2(2):46-9.
39. Keteyian SJ, Piña IL, Hibner BA, Fleg JL. Clinical role of exercise training
in the management of patients with chronic heart failure. J Cardiopulm
Rehabil Prev. 30(2):67-76.
40. Juenger J, Schellberg D, Kraemer S, Haunstetter A, Zugck C, Herzog W, et
al. Health related quality of life in patients with congestive heart failure:
comparison with other chronic diseases and relation to functional variables.
58

Heart. 2002;87(3):235-41.
41. Joseph SM, Novak E, Arnold SV, Jones PG, Khattak H, Platts AE, et al.
Comparable performance of the kansas city cardiomyopathy questionnaire in
patients with heart failure with preserved and reduced ejection fraction. Circ
Heart Fail. 2013;6(6):1139-46.
42. Heo S, Lennie TA, Okoli C, Moser DK. Quality of life in patients with heart
failure: ask the patients. Heart Lung. 2009;38(2):100-08.
43. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM.
Trends in prevalence and outcome of heart failure with preserved ejection
fraction. N Engl J Med. 2006;355(3):251-59.
44. Effect of enalapril on survival in patients with reduced left ventricular
ejection fractions and congestive heart failure. The SOLVD Investigators. N
Engl J Med. 1991;325(5):293-302.
45. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect
of carvedilol on survival in severe chronic heart failure. N Engl J Med.
2001;344(22):1651-58.
46. Moss AJ, Zareba W, Hall WJ, Klein H, Wilver DJ, Dannom DS, et al.
Prophylactic implantation of a defibrillator in patients with myocardial
infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877-83.
Lampiran 1. Ethical Clearance
Lampiran 2. Surat izin penelitian
Lampiran 3. Informed consent
Lampiran 4. Data hasil penelitian
No. Nama No. RM LVEF MLHFQ MLHFQ MLHFQ Skor
(Akronim) (dalam dimensi dimensi dimensi total
%) Fisik Umum Emosi MLHFQ
1. Pu C534490 49 4 6 1 11
2. Su C454763 74 1 6 8 15
3. La C540902 74 3 5 3 11
4. St C142510 56 9 11 2 22
5. MZ C492011 52 6 3 0 9
6. TD C560053 62 13 14 9 36
7. SSp C581213 16 11 7 2 20
8. SSb C576319 60 20 26 8 54
9. SSm C229017 74 1 9 4 14
10. Sj C404533 30 32 26 16 74
11. SN C576368 65 26 24 18 68
12. KD C342953 83 7 7 5 19
13. IT C551953 39 5 14 0 19
14. GT C583000 69 6 7 6 19
15. Sn C479650 41 1 13 6 20
16. Rb C582527 78 6 3 1 10
17. Snn C572396 66 21 14 6 41
18. KS C560723 69 13 13 0 26
19. Tj C569782 49 6 12 9 27
20. JS C582841 86 14 7 18 39
21. Uw C583150 74 28 30 15 73
22. Dj C583145 34 16 13 11 40
23. NS C576780 69 8 3 4 15
24. AS C573745 36 6 16 0 22
25. Sr C549228 87 9 13 0 22
26. SP C573292 65 16 16 8 40
27. AN C584647 63 22 23 5 50
28. DS C584019 64 8 4 8 20
29. DY C228963 61 18 12 12 47
30. Ag C371070 67 17 20 8 45
31. ADL C382344 64 25 28 21 74
32. Ms C184998 62 4 3 8 15
Lampiran 5. Hasil analisis statistik SPSS versi 21

Jenis Kelamin

Frequency Percent Valid Percent Cumulative


Percent

Perempuan 19 59,4 59,4 59,4

Valid Laki-laki 13 40,6 40,6 100,0

Total 32 100,0 100,0

Umur

Frequency Percent Valid Percent Cumulative


Percent

24 1 3,1 3,1 3,1


31 1 3,1 3,1 6,3

32 1 3,1 3,1 9,4

37 1 3,1 3,1 12,5

40 1 3,1 3,1 15,6

46 1 3,1 3,1 18,8

47 2 6,3 6,3 25,0

48 1 3,1 3,1 28,1

50 1 3,1 3,1 31,3

53 1 3,1 3,1 34,4

Valid 54 4 12,5 12,5 46,9


55 3 9,4 9,4 56,3

56 3 9,4 9,4 65,6

57 2 6,3 6,3 71,9

58 1 3,1 3,1 75,0

60 2 6,3 6,3 81,3

61 2 6,3 6,3 87,5

63 1 3,1 3,1 90,6

64 1 3,1 3,1 93,8

66 2 6,3 6,3 100,0

Total 32 100,0 100,0


NYHA

Frequency Percent Valid Percent Cumulative


Percent

NYHA kelas I 15 46,9 46,9 46,9

NYHA kelas II 13 40,6 40,6 87,5


Valid
NYHA kelas III 4 12,5 12,5 100,0

Total 32 100,0 100,0

LVH

Frequency Percent Valid Percent Cumulative


Percent

Tidak 12 37,5 37,5 37,5

Valid Ya 20 62,5 62,5 100,0

Total 32 100,0 100,0

Diuretik

Frequency Percent Valid Percent Cumulative


Percent

Tidak 12 37,5 37,5 37,5

Valid Ya 20 62,5 62,5 100,0

Total 32 100,0 100,0

Beta Blocker

Frequency Percent Valid Percent Cumulative


Percent

Tidak 16 50,0 50,0 50,0


Valid Ya 16 50,0 50,0 100,0

Total 32 100,0 100,0

Ca channel Blocker

Frequency Percent Valid Percent Cumulative


Percent

Tidak 26 81,3 81,3 81,3

Valid Ya 6 18,8 18,8 100,0


Total 32 100,0 100,0
Digoxin

Frequency Percent Valid Percent Cumulative


Percent

Tidak 25 78,1 78,1 78,1

Valid Ya 7 21,9 21,9 100,0

Total 32 100,0 100,0

Antiplatelet

Frequency Percent Valid Percent Cumulative


Percent

Tidak 19 59,4 59,4 59,4

Valid Ya 13 40,6 40,6 100,0

Total 32 100,0 100,0

Nitrat

Frequency Percent Valid Percent Cumulative


Percent

Tidak 14 43,8 43,8 43,8

Valid Ya 18 56,3 56,3 100,0

Total 32 100,0 100,0

ACE inhibitor

Frequency Percent Valid Percent Cumulative


Percent

Tidak 19 59,4 59,4 59,4

Valid Ya 13 40,6 40,6 100,0

Total 32 100,0 100,0


Trombolitik

Frequency Percent Valid Percent Cumulative


Percent

Tidak 16 50,0 50,0 50,0

Valid Ya 16 50,0 50,0 100,0

Total 32 100,0 100,0

Statistics
Umur

Valid 32
N
Missing 0
Mean 52,41
Median 55,00
Mode 54
Std. Deviation 10,191
Minimum 24
Maximum 66

Case Processing Summary

Cases

Valid Missing Total

N Percent N Percent N Percent

LVEF 32 100,0% 0 0,0% 32 100,0%


Dimensi Fisik 32 100,0% 0 0,0% 32 100,0%
Dimensi Umum 32 100,0% 0 0,0% 32 100,0%
Dimensi Emosi 32 100,0% 0 0,0% 32 100,0%
MLHFQ total 32 100,0% 0 0,0% 32 100,0%

Descriptives

Statistic Std. Error

Mean 60,56 2,957

95% Confidence Interval for Lower Bound 54,53


Mean Upper Bound 66,59

LVEF 5% Trimmed Mean 61,30

Median 64,00

Variance 279,738

Std. Deviation 16,725


Minimum 16

Maximum 87

Range 71

Interquartile Range 23

Skewness -0,796 0,414

Kurtosis 0,431 0,809


Mean 11,94 1,503
95% Confidence Interval for Lower Bound 8,87
Mean Upper Bound 15,00
5% Trimmed Mean 11,51
Median 9,00
Variance 72,319
Dimensi Fisik Std. Deviation 8,504
Minimum 1
Maximum 32
Range 31
Interquartile Range 12
Skewness 0,711 0,414
Kurtosis -0,412 0,809
Mean 12,81 1,389
95% Confidence Interval for Lower Bound 9,98
Mean Upper Bound 15,65
5% Trimmed Mean 12,44
Median 12,50
Variance 61,770
Dimensi Umum Std. Deviation 7,859
Minimum 3
Maximum 30
Range 27
Interquartile Range 10
Skewness 0,717 0,414
Kurtosis -0,434 0,809
Mean 6,94 1,029
95% Confidence Interval for Lower Bound 4,84
Mean Upper Bound 9,04
5% Trimmed Mean 6,60
Median 6,00
Dimensi Emosi
Variance 33,867
Std. Deviation 5,820
Minimum 0
Maximum 21
Range 21
Interquartile Range 7
Skewness 0,789 0,414
Kurtosis -0,013 0,809
Mean 31,78 3,531

95% Confidence Interval for Lower Bound 24,58


Mean Upper Bound 38,98

5% Trimmed Mean 30,68

Median 22,00

Variance 398,886

MLHFQ total Std. Deviation 19,972

Minimum 9

Maximum 74

Range 65

Interquartile Range 28

Skewness 0,946 0,414

Kurtosis -0,166 0,809

Tests of Normality

Shapiro-Wilk

Statistic df Sig.

LVEF 0,942 32 0,085


Umur 0,890 32 0,004
NYHA 0,769 32 0,000

a. Lilliefors Significance Correction

Correlations

LVEF Dimensi Fisik Dimensi Emosi MLHFQ total

Pearson Correlation 1 -0,057 0,099 -0,046

LVEF Sig. (2-tailed) 0,757 0,589 0,804

N 32 32 32 32
Pearson Correlation -0,057 1 0,669** 0,951**
Dimensi Fisik Sig. (2-tailed) 0,757 0,000 ,000
N 32 32 32 32
**
Pearson Correlation 0,099 0,669 1 0,795**
Dimensi Emosi Sig. (2-tailed) 0,589 0,000 0,000
N 32 32 32 32
Pearson Correlation -0,046 0,951** 0,795** 1
MLHFQ total Sig. (2-tailed) 0,804 0,000 0,000

N 32 32 32 32
**. Correlation is significant at the 0.01 level (2-tailed).
Lampiran 6. Kuesioner Minnesota Living with Heart Failure
Lampiran 7. Dokumentasi penelitian
Lampiran 8. Biodata Mahasiswa

BIODATA MAHASISWA

Identitas
Nama : Alfredo
NIM : 22010112130140
Tempat/tanggal lahir : Jakarta, 10 Maret 1994
Jenis kelamin : laki-laki
Alamat : Jl. Gondang Timur IV No. 66B, Semarang
Nomor HP : 087887760808
e-mail : paulusalfredo@gmail.com

Riwayat Pendidikan Formal


1. SD : SD San Marino, Jakarta. Lulus tahun : 2006
2. SMP : SMP San Marino, Jakarta. Lulus tahun : 2009
3. SMA : SMAN 2 Jakarta. Lulus tahun : 2012
4. FK UNDIP : Masuk tahun : 2012